| Code | CSB-RA326981MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Tilvestamab, targeting AXL (AXL receptor tyrosine kinase), a member of the TAM receptor family. AXL plays a critical role in regulating cellular processes including survival, proliferation, migration, and immune modulation. Upon binding its ligand Growth Arrest-Specific 6 (GAS6), AXL activates downstream signaling pathways such as PI3K/AKT and MAPK/ERK. Aberrant AXL expression and activation have been implicated in multiple pathological conditions, particularly in cancer progression, metastasis, therapeutic resistance, and immune evasion across various malignancies including non-small cell lung cancer, acute myeloid leukemia, and triple-negative breast cancer.
Tilvestamab represents a therapeutic antibody designed to inhibit AXL signaling by blocking ligand binding and promoting receptor degradation. This biosimilar antibody provides researchers with a valuable tool for investigating AXL-mediated mechanisms in oncology, studying tumor microenvironment interactions, exploring resistance mechanisms to targeted therapies, and evaluating potential therapeutic strategies in preclinical disease models.
There are currently no reviews for this product.